Management of Hepatitis B Infection

  • Authors: Harry L. A. Janssen, MD, PhD; Milan J. Sonneveld, MD, PhD, MSc (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 5/25/18 (What's New)


    Endpoints of Nucleos(t)ide Analogue Therapy
    • Maintenance of undetectable HBV DNA levels is the key on-treatment goal in nucleos(t)ide analogue–treated patients
      • In HBeAg-positive patients, the definitive endpoint for therapy is HBeAg seroconversion. Treatment may be discontinued in patients without cirrhosis who have achieved this endpoint and completed ≥ 12 months of consolidation therapy after the appearance of anti-HBe (Table 9)[Terrault 2018]

        • AASLD recommends indefinite treatment for patients with cirrhosis[Terrault 2018]
    Monitoring Patient Response to Nucleos(t)ide Analogues
      Adherence to Nucleos(t)ide Analogues
      Management of Nucleos(t)ide Analogue–Experienced Patients and Patients With Antiviral Resistance
        Managing Lamivudine Resistance
          Managing Adefovir Resistance
            Managing Telbivudine Resistance
              Managing Entecavir and Tenofovir Resistance

            Action required